NEW YORK (GenomeWeb News) - Millenium Pharmaceuticals said Tuesday it has identified a genomic biomarker during Phase II trials of a cardiovascular disease drug.
The company said it has found that 11.3 percent of patients treated with its MLN1202 monoclonal antibody had a reduction of C-reactive protein (CRP), and that CRP reductions were more likely in patients with a SNP that was identified in 53 percent of the study population.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.